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We would like to highlight two fundamental problems in aspects of the design and statistical 
analysis utilised by Harris et al. in their paper which was published in the JME 
2019;22(7):691-697. We think the problems which we have identified with the matching of 
the myasthenia-gravis (MG) patients to non-MG patients and the statistical analysis applied 
to the resulting retrospective matched cohort data were capable of affecting the validity of 
some of the reported study findings. 
 
Study Design- matched cohort of Refractory MG and non-MG patients 
The non-MG patients were randomly matched to each MG patient at a ratio of 4:1 on age at 
index date, sex and general practice as controls, having been assigned the same index date 
as that of the MG patient (i.e. date of first diagnosis of MG) and with the additional 
requirement of having at least 12 months of data available prior to the index date. The 
follow-up period was defined as “the day after the index date until the earliest of the 
following: (a) the patient transferred out of the practice, (b) the last date of data collection 
or (c) the study end date”, which according to the reported results ranged over several years 
in duration.  In other words, the authors had assumed a time-to-event framework for their 
matched cohort, without due regard to its implication on the main endpoints of interest to 
the study, which they had summarised as healthcare resource utilisation.  
 
According to the literature, the validity of the matched cohort design and analysis of the 
resulting data assume as applied by the authors would hold only if there is no loss to follow-
up.1-2 Consequently, if some individuals are lost during follow-up, then the cohorts are only 
matched at the starting date (i.e. at index date). Indeed, the longer the duration of follow-
up, the more impactful would be the problem of increasing loss of comparability between 
the two groups on the study findings. This is likely in the case of differential follow-up 
periods, and /or, differential attrition between cohorts.  
 
Statistical Analysis of the matched cohort  
It is, of course, impossible to control losses to follow-up during the study period and this 
poses a major problem which was not addressed in the statistical analysis, making 
comparability of the MG patients and their controls difficult to justify. The paper reported 
the median length of follow-up (interquartile range [IQR]) as 74.28 (43.45–111.81) months 
for the refractory MG cohort and 63.19 (28.57–97.73) months for the non-MG control 
cohort (p=.0704). The median difference in follow-up of more than 11 months between the 
two groups could not be justifiably ignored as irrelevant, especially for such study endpoints 
that involved count data over the follow-up period. Indeed, none of the endpoints of 
interest was about time-to-event (i.e. risk assessment). 
 
By failing to provide any justification for inadvertently assuming that the matched groups 
would remain comparable over the years of follow-up periods, the authors were wrong on 
two counts: (1) by their ignoring the matching variables in the statistical analysis, and more 
importantly,3-4 (2) by estimating count endpoints over unequal periods of follow-up 
between the two groups. The person-years approach could not adequately account for the 
likelihood of non-comparability. Moreover, their analysis does not provide information on 












The mistakes we have highlighted are not uncommon among burden of disease as well as 
healthcare resource utilization studies in real world settings. These studies usually involve 
the comparison of patients with a particular disease of interest with those free of the 
disease (as controls) and the matched cohort design is very popular. The impact of the 
problems described above might be minimized if the follow-up duration is restricted to a 
short time-frame- the use of a maximum of one-year follow-up period is common.  The 
outcomes of interest for these studies are often based on count data, which rely on 
equitable duration of assessment between the two groups for comparison.  
 
A pragmatic solution, which might minimize these problems to an acceptable level (i.e. 
without significantly impacting the study results) would be to ensure that only non-MG 
patients with similar follow-up durations as that of the MG patient, are eligible for 
consideration as potential controls to the MG patient. In practice, we match each MG 
patient to eligible non-MG candidates additionally (i.e. on duration of follow-up), such that 
the follow-up periods for the matched patients- the MG patient and control(s) are within a 
short interval of each other- such as a month or a little more but no more than a year.5-10  
 
Like the authors, we have assumed that apart from the matching variables, there are no 
other significant sources of bias in terms of measured and unmeasured confounding. We 
acknowledge that the resulting controls would be a limited subset of the general population 
of non-MG patients (i.e. only those with similar enrolment record as the MG population in 
the database). However, the approach could significantly reduce the problem of 
comparability of the two groups, which is critical to the validity of the study results. This will 
restrict the source of the comparability problem to the increasing loss of the matching effect 
due to the increasing duration of follow-up, which can be addressed by accommodating the 
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